Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 ConsortiumMieke Van Hemelrijck, Michael Fahey, Antti Rannikko et al.|European Urology|2018Cited by 93
Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance InitiativeArveen Kalapara, Artitaya Lophatananon, Jan Verbeek et al.|European Urology Oncology|2019Cited by 37
Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance CohortsFrank‐Jan H. Drost, Nicole Benfante, Daan Nieboer et al.|European Urology|2019Cited by 24
Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cellsSyed Minhaj Uddin Ahmed, Yoshiyuki Kakehi|Oncology Reports|2014Cited by 10